Related Experiment Video
Updated: Mar 11, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
11.7K
Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma
Pier Luigi Zinzani1, Alessandro Broccoli1
1Institute of Hematology L. e A. Seràgnoli, University of Bologna, Via Massarenti, 9, Bologna 40138, Italy.
Hematology/Oncology Clinics of North America
|November 28, 2016
Summary
Primary mediastinal B-cell lymphoma has a high cure rate, but relapsed cases have a poor prognosis. Optimal initial treatment and identifying patients needing radiotherapy are crucial for better outcomes.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Primary mediastinal B-cell lymphoma (PMBCL) offers a high cure rate with long-term survival for most patients.
- However, relapsed or refractory disease significantly worsens the prognosis, highlighting the need for effective initial therapies.
Purpose of the Study:
- To emphasize the critical importance of selecting the most effective initial chemoimmunotherapy regimen for PMBCL.
- To explore the role of positron emission tomography (PET) in guiding decisions regarding postinduction radiotherapy for consolidation.
Main Methods:
- Review of current treatment strategies for PMBCL.
- Analysis of prognostic factors and the utility of imaging in treatment planning.
Main Results:
- The choice of initial chemoimmunotherapy is pivotal for achieving cure.
- Positron emission tomography scans can reliably identify patients who may benefit from consolidation radiotherapy.
Conclusions:
- Optimizing initial therapy and judicious use of consolidation radiotherapy, guided by PET imaging, are key to improving outcomes in PMBCL.
- Development of novel therapies targeting tumor biology may further enhance disease control.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K